tbuckley/cabot-search huggingface dataset:
Conflict of Interest in Seminal Hepatitis C Virus and Cholesterol Management Guidelines
Authors: Akilah A. Jefferson, Steven D. Pearson
Journal: JAMA Internal Medicine (2017)

<h3>Importance</h3> Little is known regarding whether Institute of Medicine (IOM) standards for managing conflicts of interest (COI) have been met in the development of recent important clinical guidelines. <h3>Objective</h3> To evaluate adherence to the IOM standards for limits on commercial COI, guideline development, and evaluation of evidence by the 2013 American College of Cardiology and American Heart Association cholesterol management guideline and the 2014 American Association for the Study of Liver Diseases and Infectious Diseases Society of America hepatitis C virus management guideline. <h3>Design, Setting, and Participants</h3> This study was a retrospective document review of the June 2014 print version of the cholesterol guideline and the final September 2015 print version of the hepatitis C virus guideline. Each guideline was assessed for adherence to the IOM standards for commercial COI published in the 2011 special report<i>Clinical Practice Guidelines We Can Trust</i>. <h3>Main Outcomes and Measures</h3> The IOM standards call for no commercial COI among guideline committee chairs and cochairs and for less than 50% of committee members to have commercial COI. Guideline and contemporaneous article disclosure statements were used to evaluate adherence to these standards. Each guideline was also reviewed for adherence to other IOM standards for guideline development and evidence review. <h3>Results</h3> Among the 16 cholesterol guideline committee members, 7 (44%) disclosed commercial COI, all 7 reported industry-sponsored research, and 6 (38%) also reported consultancy. Of 3 guideline chairs and cochairs, 1 (33%) disclosed commercial COI. Review of contemporaneous articles identified additional commercial COI. Among the 29 hepatitis C virus guideline committee members, 21 (72%) reported commercial COI. Eighteen (62%) disclosed industry-sponsored research, 10 (34%) served on advisory boards, 5 (17%) served on data safety monitoring boards, 3 (10%) were consultants, and 3 (10%) reported other honoraria. Of 6 guideline cochairs, 4 (67%) disclosed commercial COI. All 4 disclosed additional COI in other publications that were not listed in their guideline disclosures. Contemporaneous literature review revealed an additional cochair with commercial COI. Of the 9 IOM guideline development and evidence standards, the cholesterol guideline met 5 (56%), and the hepatitis C virus guideline met them all. <h3>Conclusions and Relevance</h3> Neither the cholesterol guideline nor the hepatitis C virus guideline fully met the IOM standards for commercial COI management, and discordance between committee leader guideline disclosures and those in contemporaneous articles was common. Adherence to additional IOM standards for guideline development and evidence review was mixed. Adoption of consistent COI frameworks across specialty societies may help ensure that clinical guidelines are developed in a transparent and trustworthy manner.
Edwin Thomas Melley
Authors: W J S T Shaw
Journal: BMJ (2017)

Edwin Thomas Melley (“Eddie”) was born in Redditch, Worcestershire, where he was to practice medicine for most of his professional life. Having turned down an offer to read veterinary science in London, he qualified from Birmingham University Medical School in 1954.

His house jobs at Birmingham General Hospital were followed by two years of national service, during which he was stationed mainly in Hohne, west Germany. While there he married Barbara. They had two daughters and a son, but sadly their younger daughter died from …
Very High Rate of Leukemic Transformation and Poor Survival in Patients with Lower Risk Myelodysplastic Syndrome (MDS) Who Dynamically Acquire FLT3 Molecular Alteration (FLT3m): Study of 290 MDS Patients with Sequential Mutation Analysis
Authors: Koichi Takahashi, Elias J. Jabbour, Xuemei Wang, Hady Ghanem, Naveen Pemmaraju, Farhad Ravandi, Jorge E. Cortes, Stefan Faderl, Tapan M. Kadia, Gautam Borthakur, William G. Wierda, Sherry A. Pierce, Zeev Estrov, Hagop M. Kantarjian, Guillermo Garcia-Manero
Journal: Blood (2012)
Pharmacogenetic Study of Deferasirox, An Iron Chelating Agent
Authors: Hyoung Jin Kang, Ji Won Lee, Ji-Yeob Choi, Nam Hee Kim, Mi Kyung Jang, Chang-Woo Yeo, Sang-Seop Lee, Eun Jong Han, Hyery Kim, Kyung Duk Park, Hee Young Shin, Jae-Gook Shin, Hyo Seop Ahn
Journal: Blood (2010)
Low Incidence of Cytogenetically-Defined MDS/AML among Newly Diagnosed Patients Treated According to Total Therapy 1 (TT 1) or Total Therapy 2 (TT 2).
Authors: Raymond Thertulien, Bart Barlogie, Jeffrey Sawyer, Clyde Bailey, Maureen Reiner, Erik Rasmussen, Athanasios Fassas, Maurizio Zangari, Guido Tricot
Journal: Blood (2004)
Patients with Polycythemia Vera and Essential Thrombocytosis Have a Higher Risk of Prior or Concurrent Tumors Compared to Patients with Secondary Thrombocytosis
Authors: Krisstina Gowin, Caroline Irene Piatek, Siamak Saadat, Karren Cuadra, Pedram Razavi, Ronald Tang, Casey L. O'Connell
Journal: Blood (2010)
Mosquito-Disseminated Insecticide for Citywide Vector Control and Its Potential to Block Arbovirus Epidemics: Entomological Observations and Modeling Results from Amazonian Brazil
Authors: Fernando Abad-Franch, Elvira Zamora-Perea, Sérgio L. B. Luz
Journal: PLoS Medicine (2017)

Mosquito-borne viruses threaten public health worldwide. When the ratio of competent vectors to susceptible humans is low enough, the virus's basic reproductive number (R0) falls below 1.0 (each case generating, on average, <1.0 additional case) and the infection fades out from the population. Conventional mosquito control tactics, however, seldom yield R0 < 1.0. A promising alternative uses mosquitoes to disseminate a potent growth-regulator larvicide, pyriproxyfen (PPF), to aquatic larval habitats; this kills most mosquito juveniles and substantially reduces adult mosquito emergence. We tested mosquito-disseminated PPF in Manacapuru, a 60,000-inhabitant city (~650 ha) in Amazonian Brazil.We sampled juvenile mosquitoes monthly in 100 dwellings over four periods in February 2014-January 2016: 12 baseline months, 5 mo of citywide PPF dissemination, 3 mo of focal PPF dissemination around Aedes-infested dwellings, and 3 mo after dissemination ended. We caught 19,434 juvenile mosquitoes (66% Aedes albopictus, 28% Ae. aegypti) in 8,271 trap-months. Using generalized linear mixed models, we estimated intervention effects on juvenile catch and adult emergence while adjusting for dwelling-level clustering, unequal sampling effort, and weather-related confounders. Following PPF dissemination, Aedes juvenile catch decreased by 79%-92% and juvenile mortality increased from 2%-7% to 80%-90%. Mean adult Aedes emergence fell from 1,077 per month (range 653-1,635) at baseline to 50.4 per month during PPF dissemination (range 2-117). Female Aedes emergence dropped by 96%-98%, such that the number of females emerging per person decreased to 0.06 females per person-month (range 0.002-0.129). Deterministic models predict, under plausible biological-epidemiological scenarios, that the R0 of typical Aedes-borne viruses would fall from 3-45 at baseline to 0.004-0.06 during PPF dissemination. The main limitations of our study were that it was a before-after trial lacking truly independent replicates and that we did not measure mosquito-borne virus transmission empirically.Mosquito-disseminated PPF has potential to block mosquito-borne virus transmission citywide, even under adverse scenarios. Our results signal new avenues for mosquito-borne disease prevention, likely including the effective control of Aedes-borne dengue, Zika, and chikungunya epidemics. Cluster-randomized controlled trials will help determine whether mosquito-disseminated PPF can, as our findings suggest, develop into a major tool for improving global public health.
Effect of Elliptical LV Outflow Tract Geometry on Classification of Aortic Stenosis in a Multidisciplinary Heart Team Setting
Authors: Mani Arsalan, John J. Squiers, Giovanni Filardo, Benjamin Pollock, J. Michael DiMaio, Benjamin Parva, Ambarish Gopal, Amanda C. Mahoney, David L. Brown, Michael J. Mack, Paul A. Grayburn
Journal: JACC. Cardiovascular imaging (2017)
Reduced Intensity Hematopoietic Stem Cell Transplantation for Treatment of Class 3 Lucarelli Severe Thalassemia Patients.
Authors: Suradej Hongeng, Samart Pakakasama, Ampaiwan Chuansumrit, Nongnuch Sirachainan, Thanyachai Sura, Suporn Chancharunee, Artit Ungkanont, Saengsuree Jootar
Journal: Blood (2006)
Predictive factors before and after neoadjuvant chemotherapy for breast cancer
Authors: B. C. Pestalozzi, R. Caduff, C. Rageth, D. Fink, Z. Varga
Journal: Journal of Clinical Oncology (2004)

798 Background: Tumor cell expression of estrogen receptors (ER), progesterone receptors (PR), and Her2/neu/c-erbB-2 receptors (Her2) are generally accepted predictive factors used for choosing treatment in breast cancer. It is believed that chemotherapy has no effect on ER, PR, and/or Her2 expression although this has not been thoroughly investigated. Methods: We compared predictive factors determined on pretreatment core biopsy material with determinations on the definitive surgical specimens in 24 consecutive patients (pts) treated with neoadjuvant chemotherapy for locally advanced breast cancer. Three pts were excluded due to insufficient pretreatment material (2), or complete pathologic remission (1) precluding comparison. The 21 evaluable pts had a median age = 48 (31–65); invasive ductal/lobular = 14/7; G1/G2/G3 = 1/11/9. Pretreatment stage: cT2/T3/T4/ unknown = 3/9/8/1; cN0/N1/N2/unknown = 5/12/3/1; cM0/cM1 = 17/4. Chemotherapy: Fluorouracil-Epirubicin(Epi)-Cyclophosphamid/Epi-docetaxel(doc)/both/doc alone = 12/6/1/2. Number of cycles: 2 (1pt), 3 (11pts), 4 (4pts), 5 (1pt), 6 (4pts). Results: (see Table below): Comparing pre-treatment with post-chemotherapy results predictive factors were changed in 10–33% (ER 10%, PR 19%, Her2 by IHC 33%, Her2 by FISH 14%). Conclusions: Determinations of predicive factors may change after neoadjuvant chemotherapy. The reasons for and the significance of these variations are largely unknown. Nevertheless, it is advisable to measure predictive factors more than once during the disease course. No significant financial relationships to disclose.
Allogeneic Stem Cell Transplantation for Children with Advanced Primary MDS: Results from the EWOG-MDS Study Group Employing a Pre-Transplant Preparative Regimen with Busulfan, Cyclophosphamide and Melphalan.
Authors: Charlotte Marie Niemeyer, Marco Zecca, Elisabeth Korthoff, Ulrich Duffner, Felix Zintl, Wolfram Ebell, Jan Starý, Dagmar Dilloo, Christina Peters, Markus Schmugge, Petr Sedlacek, Chiara Messina, Marry van Heuvel, Eva Bergstraesser, Monika Trebo, Peter Noellke, Franco Locatelli
Journal: Blood (2004)
Treatment of Myeloma Cast Nephropathy (MCN): A Randomized Trial Comparing Intensive Haemodialysis (HD) with High Cut-Off (HCO) or Standard High-Flux Dialyzer in Patients Receiving a Bortezomib-Based Regimen (the MYRE Study, by the Intergroupe Francophone du Myélome (IFM) and the French Society of Nephrology (SFNDT))
Authors: Frank Bridoux, Brigitte Pegourie, Karine Augeul-Meunier, Bruno Royer, Bertrand Joly, Thierry Lamy, Brigitte Kolb, Lofti Benboubker, Bertrand Arnulf, Arnaud Jaccard, Sylvie Chevret, Jean-Paul Fermand
Journal: Blood (2016)
Simultaneous Detection of Genomic Rearrangements In Myelodysplastic Syndromes (MDS) with the Multiplex Ligation-Dependent Probe Amplification (MLPA) Assay
Authors: Oronzo Scarciolla, Alberto Fragasso, Clara Mannarella, Angela Ciancio, Rosa Anna Cifarelli, Massimo Gentile, Catia Dininno, Carla Mazzone, Anna Grazia Recchia, Pasquale Servillo, Ernesto Vigna, Paola Casieri, Lisa Anelli, Fortunato Morabito, Giorgina Specchia
Journal: Blood (2010)
LONG-TERM RESULTS of the GIMEMA VTD Consolidation TRIAL In Autografted MULTIPLE Myeloma PATIENTS (VEL-03-096): IMPACT of Minimal RESIDUAL DISEASE Detection by REAL Time Quantitative PCR On LATE Recurrences and Overall SURVIVAL
Authors: Marco Ladetto, Simone Ferrero, Daniela Drandi, Federica Cavallo, Luigia Monitillo, Paola Ghione, Sara Barbiero, Mariella Grasso, Fausto Rossini, Tommasina Guglielmelli, Clotilde Cangialosi, Anna Marina Liberati, Vincenzo Callea, Tommaso Caravita, Luca De Rosa, Francesco Pisani, Antonietta Pia Falcone, Patrizia Pregno, Alberto Rocci, Roberto Passera, Mario Boccadoro, Antonio Palumbo
Journal: Blood (2011)
Efficacy and Safety of Hematopoietic Stem Cell Remobilization with Plerixafor (Mozobil®) + G-CSF In Adult Patients with Non-Hematologic Malignancies
Authors: Mitchell E. Horwitz, Edward Gorak, Peter Holman, Edward Libby, Dirk Huebner, Purvi D Mody, Jeffrey R. Schriber
Journal: Blood (2010)
Graft-Versus-Host Disease or Infection: Rapid Detection of HLA Mismatch-Reactive T Cells Ex Vivo Can Facilitate Diagnosis and Guide Therapy after Allogeneic Transplantation.
Authors: Eva Distler, Simone Thomas, Elke Schuerer, Cedrik Britten, Martin Schuler, Christoph Huber, Karin Kolbe, Thomas Woelfel, Ralf Meyer, Wolfgang Herr
Journal: Blood (2007)
LSD1 Inhibitor Activates Retinoic Acid Pathway in MLL Fusion Positive Acute Myeloid Leukemia
Authors: Mio Yano, Toshihiko Imamura, Kenichi Sakamoto, Hideki Yoshida, Atsushi Fujiki, Yoshifumi Hirashima, Hiroyuki Ishida, Hajime Hosoi
Journal: Blood (2012)
Cerebral Blood Flow-Velocity Is Associated with Increased Leukocyte Count and Systolic Blood Pressure in HbSS but Not HbSC
Authors: Raffaela Colombatti, Soundrie Padayachee, Corrina Macmahon, Sukhleen Momi, Claire Jane Hemmaway, Maddalena Casale, Baba Inusa
Journal: Blood (2015)
Mechanical Thrombectomy for Acute Ischemic Stroke
Authors: Gursant S. Atwal, Adnan H. Siddiqui
Journal: JAMA Neurology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Exercise Dynamics in Secondary Mitral Regurgitation
Authors: Philippe B. Bertrand, Ehud Schwammenthal, Robert A. Levine, Pieter M. Vandervoort
Journal: Circulation (2017)

Secondary mitral valve regurgitation (MR) remains a challenging problem in the diagnostic workup and treatment of patients with heart failure. Although secondary MR is characteristically dynamic in nature and sensitive to changes in ventricular geometry and loading, current therapy is mainly focused on resting conditions. An exercise-induced increase in secondary MR, however, is associated with impaired exercise capacity and increased mortality. In an era where a multitude of percutaneous solutions are emerging for the treatment of patients with heart failure, it becomes important to address the dynamic component of secondary MR during exercise as well. A critical reappraisal of the underlying disease mechanisms, in particular the dynamic component during exercise, is of timely importance. This review summarizes the pathophysiological mechanisms involved in the dynamic deterioration of secondary MR during exercise, its functional and prognostic impact, and the way current treatment options affect the dynamic lesion and exercise hemodynamics in general.
Novel PDGFRA Point Mutations in Hypereosinophilic Syndrome Induce Growth Factor Independence and Leukemia in Vitro and In Vivo.
Authors: Christian Elling, Philipp Erben, Christoph Walz, Marie Frickenhaus, Mirle Schemionek, Martin Stehling, Hubert Serve, Nick C.P. Cross, Wolfgang Berdel, Carsten Mueller-Tidow, Andreas Reiter, Steffen Koschmieder
Journal: Blood (2009)
Tobacco control benefits poor people, says WHO
Authors: Anne Gulland
Journal: BMJ (2017)

Tobacco control benefits economies as well as public health, a major report from the World Health Organization has found.1

The report, published in conjunction with the National Cancer Institute of the United States, found that tobacco use costs the global economy $1 trillion (€0.94trn; £0.82trn) a year in terms of healthcare expenditure and lost productivity from ill health.

The world currently has 1.1 billion smokers aged 15 or over, around 80% of whom live in low or middle income countries. Smoking rates have fallen in most regions of the world over the past 15 years, and smoking rates among adults in Europe have fallen from 59.2% in 2000 to 47.2% in 2015. …
Can pegylated interferon improve the outcome of polycythemia vera patients?
Authors: Elena Crisà, Marco Cerrano, Eloise Beggiato, Giulia Benevolo, Giuseppe Lanzarone, Paola Maria Manzini, Alessandra Borchiellini, Ludovica Riera, Mario Boccadoro, Dario Ferrero
Journal: Journal of Hematology & Oncology (2017)

Pegylated interferon (peg-IFN) was proven by phase II trials to be effective in polycythemia vera (PV); however, it is not clear whether it could improve patient outcome compared to hydroxyurea (HU). Here, we present an observational study on 65 PV patients aged 65 years or younger, who received either peg-IFN (30) or HU (35) according to the physician choice. Median follow-up was 75 months. The two cohorts were comparable for patient and disease characteristics. Eighty-seven percent of the patients treated with peg-INF responded, with a CR rate of 70% as compared to 100 and 49% with HU, respectively. Discontinuation rate was similar in the two groups (20% in peg-IFN vs 17% in HU). JAK2 allele burden was monitored in peg-INF arm only, and a reduction was observed in 88% of the patients. No thrombotic events were observed during peg-IFN treatment compared to three on HU. Disease progression to myelofibrosis or acute myeloid leukemia occurred to a patient only in peg-INF, compared to three in HU. Overall, three second malignancies were observed during the study, two in patients who received HU only, and one in a patient largely treated HU who received also peg-IFN for 3 months. Overall survival was significantly better for peg-IFN patients compared to HU, p = 0.027. Our study, albeit limited by small patient and event number and lack of randomization, confirms the efficacy of peg-INF in PV and shows a significant survival advantage for peg-INF-treated patients. Waiting for confirming data from the ongoing phase III trials, our study can support peg-INF as a first-line treatment option for PV, at least for younger patients.
IgA and IgG Hypogammaglobulinemia Persists in Most Patients with Waldenstrom’s Macroglobulinemia Despite Therapeutic Responses, Including Complete Remissions.
Authors: Steven Treon, Andrew Branagan, Zachary Hunter, Daniel Ditzel Santos, Olivier Tournilhac, Evdoxia Hatjiharissi, Lian Xu, Robert Manning
Journal: Blood (2004)
Identification of shared and unique gene families associated with oral clefts
Authors: Noriko Funato, Masataka Nakamura
Journal: International Journal of Oral Science (2017)

Oral clefts, the most frequent congenital birth defects in humans, are multifactorial disorders caused by genetic and environmental factors. Epidemiological studies point to different etiologies underlying the oral cleft phenotypes, cleft lip (CL), CL and/or palate (CL/P) and cleft palate (CP). More than 350 genes have syndromic and/or nonsyndromic oral cleft associations in humans. Although genes related to genetic disorders associated with oral cleft phenotypes are known, a gap between detecting these associations and interpretation of their biological importance has remained. Here, using a gene ontology analysis approach, we grouped these candidate genes on the basis of different functional categories to gain insight into the genetic etiology of oral clefts. We identified different genetic profiles and found correlations between the functions of gene products and oral cleft phenotypes. Our results indicate inherent differences in the genetic etiologies that underlie oral cleft phenotypes and support epidemiological evidence that genes associated with CL/P are both developmentally and genetically different from CP only, incomplete CP, and submucous CP. The epidemiological differences among cleft phenotypes may reflect differences in the underlying genetic causes. Understanding the different causative etiologies of oral clefts is important as it may lead to improvements in diagnosis, counseling, and prevention. Oral clefts: Distinct genetic profiles characterize subtypes. Oral cleft subtypes are characterized by distinct gene profiles that may reflect differing genetic causes. Oral clefts, the most common congenital defect in humans, are associated with a large number of genes. Noriko Funato and Masataka Nakamura at the Tokyo Medical and Dental University, Japan, aimed to identify the genetic differences underlying the diverse nature of this disorder by grouping and analyzing the genes associated with different oral cleft subtypes according to their known functions. They found that different oral cleft subtypes were associated with genes with distinct functions. In particular, genes linked to the cleft lip and/or palate subtype were developmentally and genetically different from those of other oral cleft subtypes. A better understanding of the underlying genetic causes of oral clefts will allow for improved diagnosis and prevention.
Induction Therapy with “3+7” Chemotherapy Plus ATRA Followed by Consolidations with Three Courses of Idarubicin Alone and Maintenance Therapy with ATRA in Newly Diagnosed Acute Promyelocytic Leukemia (APL) Has An Excellent Leukemia-Free Survival but Minimal Toxicity in Low and Intermediate Risk Groups.
Authors: Moon-Young Choi, Yeung-Chul Mun, Se Hoon Park, Eun Kyung Cho, Jae Hoon Lee, Deog Yeon Jo, Inho Kim, Soo-Mee Bang, Sung-Soo Yoon, Seonyang Park, Byoung Kook Kim, Hawk Kim, Young Joo Min, Jae Hoo Park, Jong Jin Seo, Hyung Nam Moon, Moon Hee Lee, Cheol Soo Kim, Won Sik Lee, Young Don Joo, So Young Chung, Doyeun Oh, Dae Young Zang, Kyung Hee Lee, Myung Soo Hyun, Hong Suk Song, Heung Sik Kim, Sung Hyun Kim, Hyuk Chan Kwon, Hyo Jin Kim, Kyung Tae Park, Jin Seok Ahn, Yeon Hee Park, Myung Ju Ahn, Sung Hwa Bae, Hun-Mo Ryoo, Jung-Hye Choi, Hwi-Joong Yoon, Seung-Hyun Nam, Bong-Seog Kim, Thad T. Ghim, Chu-Myong Seong
Journal: Blood (2009)
Adverse Prognostic Impact of Vascular Endothelial Growth Factor Gene Polymorphism in Patients with Non-Hodgkin Lymphoma.
Authors: Min Kyeong Kim, Hyeon Seok Eom, Hyewon Lee, Mi Hwa Han, Hyun-Ju Kim, Weon Seo Park, Tak Yun, Sun-Young Kong
Journal: Blood (2012)
Long-Term Follow-Up of 132 Immunocompetent Primary Central Nervous System Lymphomas Treated at Leon Berard Cancer Centre: Proposition of a New Prognostic Model.
Authors: Herve Ghesquieres, Marie Pierre Sunyach, Youenn Drouet, Catherine Sebban, Catherine Chassagne, Emmanuel Jouanneau, Jerome Honnorat, Pierre Biron, Jean-Yves Blay
Journal: Blood (2007)
Molecular and Phenotypic Analysis of Philadelphia Chromosome-Positive Bilineage Leukemia: Possibility of a Lineage Switch from T-Lymphoid Leukemia Progenitor to Myeloid Cells Via PU.1 Expression.
Authors: Kazuhiro Nishii, Fumihiko Monma, Felipe Lorenzo, Naoyuki Katayama, Hiroshi Shiku
Journal: Blood (2005)